Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL LOW CALCIUM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL LOW CALCIUM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER vs EXTRANEAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% provides a hyperosmotic solution for peritoneal dialysis. Dextrose generates an osmotic gradient across the peritoneal membrane, promoting fluid and solute removal (ultrafiltration). Low calcium content helps manage hypercalcemia in patients requiring peritoneal dialysis.
Extraneal (icodextrin) is a glucose polymer that acts as an osmotic agent for peritoneal dialysis. It is absorbed from the peritoneal cavity into the bloodstream and metabolized to maltose and other oligosaccharides. Its primary mechanism is to create an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of waste products.
Intraperitoneal: 2-3 L per exchange, 4-5 exchanges daily, as prescribed by physician based on body size and residual renal function.
7.5% solution: 2 L intraperitoneally, dwell time 4–8 hours, up to 4 exchanges per day. For automated peritoneal dialysis: 2 L per cycle, typically 3–5 cycles overnight.
None Documented
None Documented
Not applicable; drug is not systematically absorbed. Dextrose has half-life of ~1.5-2 hours after absorption.
The terminal elimination half-life of icodextrin in plasma is approximately 19 hours (range 12-22 hours) following intraperitoneal administration for a dwell of 8-12 hours. This long half-life reflects slow metabolism and clearance, particularly relevant in patients with impaired renal function, leading to accumulation of maltose and other oligosaccharides.
Primarily removed via peritoneal dialysis; negligible renal excretion due to local administration. Dextrose is metabolized systemically; dialysate is drained as waste.
Icodextrin is metabolized to maltose, maltotriose, and other oligosaccharides. After intraperitoneal administration, approximately 40% of the administered dose is absorbed systemically; the absorbed icodextrin and its metabolites are primarily eliminated by renal excretion (via glomerular filtration). In patients with residual renal function, approximately 30-40% of the absorbed dose is excreted in urine over 14 days. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution